Background: Keratoacanthomas are characterized by initial rapid enlargement followed by clinical regression. A series of cyclin and cyclin-dependent kinase complexes regulate cell cycle progression. p27kip inhibits a variety of cyclin–cyclin-dependent kinase complexes in vitro and may act to hold eukaryotic cells in a quiescent state (G0). Objective: We examined expanding and regressing keratoacanthomas for expression of p27kip. Methods: An immunohistochemical method was used to visualize and count p27kip-labeled cells in 5 expanding and 15 regressing keratoacanthomas. Results: In normal epidermis p27kip was found overlying the nuclei of suprabasilar keratinocytes. In expanding keratoacanthoma there was little expression of p27kip in nuclei of atypical keratinocytes composing the tumor (1.25 ± 2.1 labeled cells per high-power field); in regressing keratoacanthoma the nuclei of most suprabasilar keratinocytes in atypical tumor aggregates contained p27kip (55.1 ± 28.6 labeled cells per high-power field). The difference was significant at P values of less than .001. Conclusion: The identification of p27kip in regressing keratoacanthoma but not in expanding keratoacanthoma suggests that p27kip may be playing a role in promoting regression of keratoacanthoma and is a potential target for pharmacologic intervention. (J Am Acad Dermatol 2000;42:473-5.)Le texte complet de cet article est disponible en PDF.
| Reprint requests: Neal S. Penneys, MD, PhD, MBA, 1402 S Grand Blvd, St Louis, MO 63104.